The Heavy Cavalry of Colorectal Cancer
What is tumor budding – and how can this novel histopathological biomarker better stratify colorectal cancer patients?
Alessandro Lugli | | Opinion
At a Glance
- Tumor budding is proposed as an additional prognostic factor in the eighth edition of the TNM Classification of Malignant Tumors 2017.
- As a biomarker of tumor progression, budding is part of the tumor microenvironment and involved in the epithelial-to-mesenchymal transition (EMT).
- Tumor budding can aid clinical decision-making in early-stage colorectal cancer.
- A 2016 International Tumor Budding Consensus Conference established a reproducible and cost-effective scoring system.
Personalized healthcare requires solid, reproducible biomarkers to stratify cancer patients into prognostic subgroups. One such factor emerging in colorectal cancer is tumor budding, a novel and promising histopathological biomarker now classified as an additional prognostic factor in the eighth edition of the TNM Classification of Malignant Tumors 2017 (1).
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.